1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia

PartnershipOC-3Positive

AI Analysis

Summary

1cBio entered an exclusive licensing agreement with Lee's Pharmaceutical Holdings Limited to develop and commercialize PARP1 inhibitor OC-3 in Greater China and Southeast Asia, with potential payments up to $27 million.

Importance:6/10

Sentiment:

0.70

licensing agreementPARP1 inhibitoroncologyGreater ChinaSoutheast Asiamilestone payments

Related Companies

$INTI $DFPH $GCAN $CHHE

Read the original article

Published by PR Newswire Clinical Trials on September 9, 2026 12:00 PM

Read Original